Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push [Globe and Mail, The (Toronto, Canada)]
Immunic, Inc. (IMUX)
Company Research
Source: Globe and Mail, The
As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception. Shares of Immunic, Inc. ( Nasdaq: IMUX ) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for an additional $200 million upon exercise of accompanying warrants. The company stated that the proceeds are expected to accelerate its transition from a research-driven organization into a fully integrated commercial-stage company. Immunic plans to use the capital to complete its ongoing Phase 3 ENSURE clinical trials of vidofludimus calcium in relapsing multiple sclerosis, with top-line data anticipated by the end of 2026. Management indicated that, pending positive results, a New Drug Application sub
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic closes $200M private placement to fund late-stage MS trials [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Closing of Oversubscribed Private Placement FinancingPR Newswire
- Immunic secures $400m fund to support commercial-stage development [Yahoo! Finance]Yahoo! Finance
- Why Immunic (IMUX) Is Up 47.2% After $400 Million MS Push And Leadership Shake-Up [Yahoo! Finance]Yahoo! Finance
- Update: Immunic Prices Private Placement, to Seek New CEO; Shares Surge [Yahoo! Finance]Yahoo! Finance
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form SCHEDULE
- IMUX's page on the SEC website